Harbin Pharmaceutical Co., Ltd. (600664.SH): Cefazoxime sodium for injection passed the generic drug consistency evaluation

Zhitongcaijing · 2d ago

Zhitong Finance App News, Harbin Pharmaceutical Co., Ltd. (600664.SH) issued an announcement. Recently, the company's subsidiary Harbin Pharmaceutical Group Pharmaceutical General Factory (“Harbin Pharmaceutical General Factory”) received the “Drug Supplement Application Approval Notice” for injectable cefazoxime sodium from the State Drug Administration [0.5g (calculated according to C13H13N5O5S2), notification number: 2026B07860; 1.0g (calculated according to C13H13N5O5S2), notification number: 2026B07866]. The quality and efficacy consistency of the above drugs through generic drugs Evaluation.

Cefazoxime for injection is used for lower respiratory infections, urinary tract infections, abdominal infections, pelvic infections, sepsis, skin and soft tissue infections, bone and joint infections, meningitis caused by Streptococcus pneumoniae or Haemophilus influenzae, and simple gonorrhea.